Lung Cancer Clinical Trials in Arizona

Showing 141-160 of 280 trials

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

NCT05094804

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.

CancerTumor, SolidMalignant Neoplasm+7 more

OncoResponse, Inc.172 participantsStarted Sep 2021

Scottsdale, Arizona, United States • Austin, Texas, United States • San Antonio, Texas, United States

COMPLETEDPHASE133 miles

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

NCT03219268

The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.

Advanced Solid TumorsHematologic NeoplasmsOvarian Cancer+7 more

MacroGenics277 participantsStarted Aug 2017

Gilbert, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +37 more locations

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Lung Cancer Trials in Other Cities

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Survival Prolongation by Rationale Innovative Genomics

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Other Conditions in Arizona